PLEASANTON, Calif., Nov. 30, 2017 -- Title21 Health Solutions, “Title21”, an innovator of integrated enterprise software for blood and marrow transplant programs supporting high-quality and world-class patient care announces plans to feature the latest version of its BMT Software Solution at the 2018 BMT Tandem Meeting in Salt Lake City, Utah at the Salt Palace Convention Center from February 21st through February 25th.
Enhanced functionality in the Title21 BMT Solution 8.5 enables the BMT patient care team to manage all data in one system from patient referral through post-transplant follow up. Title21 is scheduling demonstrations at booth #125.
New functionality in the latest release includes a complete Case Management Solution to improve the coordination of tasks and operations across the patient care team. Additionally, the system’s new Chain of Custody functionality tracks product send-outs and receipts while automatically documenting logistics and compliance data. Support for CAR-T workflows is also available.
BMT Programs are increasingly required to manage large amounts of patient, laboratory and quality data while satisfying compliance requirements for record-keeping, process control, outcomes analysis and reporting. Title21 BMT Solution provides a single, integrated system to manage core operations including Clinical Data Management, Laboratory Processing, Supplies & Equipment Tracking, ISBT 128 Labeling, Product Inventory Management, Laboratory Release, Patient Chart Review, Outcomes Analysis and Reporting. The comprehensive system integrates with clinical information systems and instruments via secure HL7 channels as well as integrates with CIBMTR for streamlined reporting.
“Title21 continues to enhance our technology to support the growing data management needs of BMT Programs as patient treatment options expand with research discoveries and breakthroughs,” said Lynn Fischer, CEO of Title21. “Title21’s track record of expanding its capabilities while delivering flexible technology speaks to our commitment to providing dynamic technology to support the long-term needs and agility of BMT Programs. We look forward to showing our latest advancements in Salt Lake City.”
To learn more about Title21 and schedule a demo at the 2018 BMT Tandem Meeting, visit www.Title21.com/BMT-Tandem-2018.
About Title21 Health Solutions
Title21 Health Solutions delivers easy-to-use, flexible and integrated technology to support health sciences organizations to gain efficiencies, improve compliance and ensure quality. Title21’s product line includes Enterprise Quality Management Solutions and an integrated, comprehensive Cellular Therapy Software. Learn more about Title21 Health Solutions at www.Title21.com.
Contact: Haley Roebuck Associate Marketing Manager 925-484-2121 [email protected]


Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Anta Sports Expands Global Footprint With Strategic Puma Stake
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 



